奥克列珠单抗
芬戈莫德
多发性硬化
医学
美罗华
复发-缓解
肿瘤科
内科学
免疫学
淋巴瘤
作者
Lisa Graille-Avy,Clémence Boutière,Camille Rigollet,Marine Perriguey,Audrey Rico,Sarah Demortière,Pierre Durozard,Frédéric Hilezian,Frédéric Vély,P Bertault-Péres,Jean Pelletier,Adil Maarouf,Bertrand Audoin
标识
DOI：10.1212/nxi.0000000000200231
摘要
Real-life studies noted that the risk of disease activity in multiple sclerosis (MS) after switching to rituximab (RTX) or ocrelizumab (OCR) may be unequal depending on prior disease-modifying therapy (DMT), with a higher risk associated with fingolimod (FING).
科研通智能强力驱动
Strongly Powered by AbleSci AI
SOLOMON
shinysparrow
cctv18
个性的紫菜
gjww
坚强的广山
寻道图强
酸化土壤改良
wangjingli666
YINZHE
可爱迪
不倦
Singularity
丹霞
紫金大萝卜
maox1aoxin
凤凰
热切菩萨
Maestro_S
pluto
皖公网安备34019202002308
